Abstract
It is widely accepted that one of the most important host-defense mechanisms against invading microorganisms is phagocytosis, followed by intracellular killing and digestion of the microorganism by phagocytic cells. Recently it was found that survival, growth and differentiation of progenitor phagocytic cells are controlled by hemopoietic colony-stimulating factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), macrophage colony-stimulating factor (M-CSF) or multi colony-stimulating factor (IL-3) (1). G-CSF induces hemopoietic precursor cells to proliferate and differentiate into neutrophils, which are one of the most important first defense lines to microbial infections (2). Recently our studies have shown that G-CSF activates the antimicrobial activity of peripheral neutrophils against pathogenic yeast such as Candida albicans in vitro (3). Furthermore, it has also been demonstrated that G-CSF treatment of neutropenic mice can protect following infection with fungi (3). These previous results suggest that G-CSF might be a useful cytokine for treatment of neutropenic patients to protect from secondary fungal infections. To treat fungal infections of neutropenic patients, antifungal drugs must often be used as a therapeutic agent. However, there is little information about the usefulness of G-CSF in combination with antifungal drugs against fungal infections. The present studies were designed to investigate the therapeutic efficacy of four antifungal drugs, i.e., amphotericin B (AMPH), flucytosine (5-FC), fluconazole (FCZ) and itraconazole (ICZ) in combination with recombinant human G-CSF against C. albicans infection in neutropenic mice induced with cyclophosphamide. The administration of G-CSF in combination with either FCZ or ICZ markedly enhanced the therapeutic effect of antifungal drugs against Candida infection. However, G-CSF administered to mice in combination with either 5-FC or AMPH resulted in no significant enhancement. These results indicate that effectiveness is dependent upon the kind of antifungal drugs used.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
N. A. Nicola and M. Vadas, Hemopoietic colony-stimulating factors, Immunol. Today 5:76 (1984).
D. Metcalf, The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors, Blood 67:257 (1986).
Y. Yamamoto, K. Uchida, T. Hasegawa, H. Friedman, T. W. Klein, and H. Yamaguchi, Recombinant G-CSF induces anti-Candida albicans activity in neutrophil cultures and protection in fungal infected mice, in: “Recent Progress in Antifungal Chemotherapy,” H. Yamaguchi, G. S. Kobayashi, and H. Takahashi, eds., Marcel Dekker, New York, (1991).
L. M. Souza, T. C. Boone, J. Gabrilove, P. H. Lai, K. M. Zesbo, D. C. Murdock, V. R. Chazin, J. Bruszewsk, H. Lu, K. K. Chen, J. Barendt, E. Platzer, M. A. S. Moore, R. Mertelsman, and K. Weite, Recombinant human granulocyte colony-stimulating factor: Effects on normal and leukemic myeloid cells, Science 232:61 (1986).
D. J. Finney, “Probit Analysis. A Statistical Treatment of the Sigmoid Response Curve,” Cambridge Univ. Press (1952).
S. Kitagawa, A. Yuo, L. M. Souza, M. Saito, Y. Miura, and F. Takaku, Recombinant human granulocyte colony-stimulating factor enhances Superoxide release in human granulocyte stimulated by chemotactic peptide, Biochem. Biophys. Res. Commun. 144:1143 (1987).
A. Yuo, S. Kitagawa, A. Okabe, Y. Komatsu, S. Itoh, and F. Takaku, Recombinant human granulocyte colony-stimulating factor repairs the abnormalities of neutrophil in patients with myelodysplastic syndromes and chronic myelogenous leukemia, Blood 70:404 (1987).
R. Sullivan, J. D. Griffin, E. R. Simons, A. I. Schafer, T. Meshulan, J. P. Fredette, A. K. Mass, A.-S. Gadenne, J. L. Leavitt, and D. A. Melnick, Effects of recombinant human granulocyte and macrophage colony-stimulating factors on signal transduction pathways in human granulocytes, J. Immunol. 139:3422 (1987).
A. N. Buckle, and N. Hogg, The effect of IFN-gamma and colony-stimulating factors on the expression of neutrophil cell membrane receptors, J. Immunol. 143:2295 (1989).
A. Yuo, S. Kitagawa, A. Ohsaka, M. Ohta, K. Miyazono, T. Okabe, A. Urabe, M. Saito, and F. Takaku, Recombinant human granulocyte colony-stimulating factor as an activator of human granulocytes: Potentiation of responses triggered by receptor-mediated agonists and stimulation of C3bi receptor expression and adherence, Blood 74:2144 (1989).
K. Weite, M. A. Bonilla, A. P. Gillion, T. C. Boone, G. K. Potter, J. L. Gabrilove, M. A. S. Moore, R. J. O’Reiley, and L. M. Souza, Recombinant human granulocyte colony-stimulating factor: Effects on hematopoiesis in normal and cyclophosphamide-treated primates, J. Exp. Med. 165:941 (1987).
M. Tamura, K. Hattori, H. Nomura, M. Oheda, N. Kubota, I. Imazeki, M. Ono, Y. Ueyama, S. Nagata, N. Shirafuji, and S. Asano, Induction of neutrophilic granulocytosis in mice by administration of purified human native granulocyte colony-stimulating factor (G-CSF), Biochem. Biophys. Res. Commun. 142:454 (1987).
M. Matsumoto, S. Matsubara, T. Matsuno, M. Tamura, K. Hattori, H. Nomura, M. Ono, and T. Yokota, Protective effect of human granulocyte colony-stimulating factor on microbial infection in neutropenic mice, Infect. Immun. 55:2715 (1987).
A. M. Cohen, D. K. Hines, E. S. Korach, and B. J. Ratzkin, In vivo activation of neutrophil function in hamsters by recombinant human granulocyte colony-stimulating factor, Infect. Immun. 56:2861 (1988).
J. VanCutsem, F. VanGerven, M.-A. Van de Ven, M. Borgers, and P. A. J. Janssen, Itraconazole, a new triazole that is orally active in aspergillosis, Antimicrob. Agents Chemother. 26:527 (1984).
J. F. Ryley and R. G. Wilson, ICI 153,066, a new orally active antifungal agent, in: “Program and abstracts of the 22nd Interscience Conference of Antimicrobial Agents and Chemotherapy,” ASM, Washington D. C. (1982).
E. Drouhet and B. Dupont, Evolution of antifungal agents: Past, present, and future, Rev. Infec. Dis. 9 (Sup 1):s4 (1987).
E. Grunberg, E. Titsworth, and M. Bennett M, Chemotherapeutic activity of 5-fluorocytosine, Antimicrob. Agents Chemother. 3:566 (1963).
M. Matsumoto, S. Matsubara, T. Matsuno, M. Ono, and T. Yokota T, Protective effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) against various microbial infections in neutropenic mice, Microb. Immunol. 34:765 (1990).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media New York
About this chapter
Cite this chapter
Yamamoto, Y., Uchida, K., Klein, T.W., Friedman, H., Yamaguchi, H. (1992). Immunomodulators and Fungal Infections: Use of Antifungal Drugs in Combination with G-CSF. In: Friedman, H., Klein, T.W., Yamaguchi, H. (eds) Microbial Infections. Advances in Experimental Medicine and Biology, vol 319. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3434-1_24
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3434-1_24
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6519-8
Online ISBN: 978-1-4615-3434-1
eBook Packages: Springer Book Archive